EHA 2022 | Expanded access study of zanubrutinib in patients with Waldenström’s macroglobulinemia
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase II expanded access study of zanubrutinib in patients with treatment-naive Waldenström’s macroglobulinemia (WM) who are unsuitable for standard chemoimmunotherapy or with relapsed/refractory (R/R) disease (NCT04052854), comparing it with the findings of the ASPEN study (NCT03053440). Overall, the study found that the safety and efficacy of zanubrutinib was similar to what was observed in the ASPEN study, demonstrating the suitability of this drug in patients who wouldn’t have been candidates for this clinical trial. In addition, the study showed that zanubrutinib could be given once daily instead of twice daily. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting fees and/or research funds from Abbvie, AstraZeneca, BeiGene, Cellectar, Janssen, Pharmacyclics, Roche, TG Therapeutics.
